Back

Insilico Medicine doses first patient in 52-week Rentosertib Phase III trial

Verifying
  • Insilico Medicine dosed the first patient in its Phase III Rentosertib trial.
  • The study will enroll 320 participants across 47 centers in China.
  • Rentosertib remains investigational and has not received regulatory approval.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.